EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fgfr3 enhancer deletion markedly improves all skeletal features in a mouse model of achondroplasia

Marco Angelozzi, Arnaud Molin, Anirudha Karvande, Ángela Fernández-Iglesias, Samantha Whipple, Andrew M Bloh, Véronique Lefebvre

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci184929 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Marco Angelozzi und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Achondroplasia, Receptor, Fibroblast Growth Factor, Type 3, Enhancer Elements, Genetic, Sequence Deletion. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, Caen University Hospital Reference Center for Rare diseases of Calcium and Phosphate Metabolism, National Institute of Arthritis and Musculoskeletal and Skin Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Achondroplasia, the most prevalent short-stature disorder, is caused by missense variants overactivating the fibroblast growth factor receptor 3 (FGFR3). As current surgical and pharmaceutical treatments only partially improve some disease features, we sought to explore a genetic approach. We show that an enhancer located 29 kb upstream of mouse Fgfr3 ( –29E ) is sufficient to confer a transgenic mouse reporter with a domain of expression in cartilage matching that of Fgfr3 . Its CRISPR/Cas9-mediated deletion in otherwise WT mice reduced Fgfr3 expression in this domain by half without causing adverse phenotypes. Importantly, its deletion in mice harboring the ortholog of the most common human achondroplasia variant largely normalized long bone and vertebral body growth, markedly reduced spinal canal and foramen magnum stenosis, and improved craniofacial defects. Consequently, mouse achondroplasia is no longer lethal, and adults are overall healthy. These findings, together with high conservation of –29E in humans, open a path to develop genetic therapies for people with achondroplasia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AchondroplasiaReceptor, Fibroblast Growth Factor, Type 3Enhancer Elements, GeneticSequence DeletionAnimalsMiceDisease Models, AnimalMice, TransgenicHumans

Stichwörter der Autor:innen

Bone biologyBone diseaseCartilageGeneticsMouse models

Substanzen

Receptor, Fibroblast Growth Factor, Type 3Fgfr3 protein, mouseFGFR3 protein, human

Förderung

  • NIAMS NIH HHS
  • Caen University Hospital Reference Center for Rare diseases of Calcium and Phosphate Metabolism
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Angelozzi, M., Molin, A., Karvande, A., Fernández-Iglesias, Á., Whipple, S., Bloh, A. M., & Lefebvre, V. (2025). Fgfr3 enhancer deletion markedly improves all skeletal features in a mouse model of achondroplasia. Journal of Clinical Investigation. https://doi.org/10.1172/jci184929

Vancouver

Angelozzi M, Molin A, Karvande A, Fernández-Iglesias Á, Whipple S, Bloh AM, et al. Fgfr3 enhancer deletion markedly improves all skeletal features in a mouse model of achondroplasia. Journal of Clinical Investigation. 2025. doi:10.1172/jci184929

BibTeX
@article{Angelozzi2025,
  author = {Angelozzi, Marco and Molin, Arnaud and Karvande, Anirudha and Fernández-Iglesias, Ángela and Whipple, Samantha and Bloh, Andrew M and Lefebvre, Véronique},
  title = {Fgfr3 enhancer deletion markedly improves all skeletal features in a mouse model of achondroplasia},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci184929}
}
Kostenlos starten →